Stryker

SYK

Market cap $142B

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Over $500 million in insider stock sales have hit three high-profile companies this month—an unsettling signal that even top executives and major stakeholders may be questioning the sustainability of recent gains.

Stryker Corporation ( SYK ) Analyst/Investor Day November 13, 2025 2:30 PM EST Company Participants Jason Beach - Vice President of Finance & Investor Relations Kevin Lobo - Chairman, CEO & President Spencer Stiles - Group President of Orthopaedics Dylan Crotty - President of Instruments Kathy Truppi J. Pierce - Group President of MedSurg & Neurotechnology Tim Lanier Viju Menon - Group President of Global Quality & Operations Debra King - VP, Chief Digital & Information Officer Jessica Mathieson Preston Wells - VP & CFO Conference Call Participants Neal Patel Robert Marcus - JPMorgan Chase & Co, Research Division Matthew Miksic - Barclays Bank PLC, Research Division Larry Biegelsen - Wells Fargo Securities, LLC, Research Division Travis Steed - BofA Securities, Research Division Ryan Zimmerman - BTIG, LLC, Research Division Pito Chickering - Deutsche Bank AG, Research Division Christopher Pasquale - Nephron Research LLC Joanne Wuensch - Citigroup Inc., Research Division Shagun Singh Chadha - RBC Capital Markets, Research Division Matthew O'Brien - Piper Sandler & Co., Research Division Joshua Jennings - TD Cowen, Research Division David Roman - Goldman Sachs Group, Inc., Research Division Conversation Jason Beach Vice President of Finance & Investor Relations Good afternoon.

Stryker Corporation (NYSE: SYK) is currently in Phase 8 of its 18-phase Adhishthana cycle on the weekly charts, and the stock has just broken its Cakra formation. This is a major bearish development within the framework and suggests a prolonged period of underperformance.

Aging populations and wage inflation are making automation economically compelling across warehouses, factories, hospitals, and service industries. The robotics market encompasses a range of industries and niches, from mature surgical systems to warehouse automation and even humanoid platforms designed for household chores.

Stryker (SYK) delivered strong Q3 2025 results, raising full-year guidance on robust organic growth across both MedSurg & Neurotechnology and Orthopaedics segments. SYK achieved double-digit organic sales and EPS growth, supported by margin expansion and successful product launches. Despite operational strength, SYK trades at a significant valuation premium to sector peers, with a PEG ratio above 2 and earnings growth in line with the S&P 500.

Stryker (SYK) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Stryker continues to deliver strong organic growth, having posted organic growth rates of around 10% for a long period of time now. The $4.9 billion Inari Medical acquisition announced this year will boost the neurovascular business and slightly increase leverage, but deleveraging attempts are quite impressive. Valuation multiples have compressed to 26x earnings, making SYK more appealing as earnings outpace share price gains and leverage ratios come down.

The headline numbers for Stryker (SYK) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Stryker's Q3 results top estimates with double-digit sales and profit growth, but shares slip as investors weigh tariff pressures despite an upbeat 2025 outlook.